SG11201702135PA - A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof - Google Patents

A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof

Info

Publication number
SG11201702135PA
SG11201702135PA SG11201702135PA SG11201702135PA SG11201702135PA SG 11201702135P A SG11201702135P A SG 11201702135PA SG 11201702135P A SG11201702135P A SG 11201702135PA SG 11201702135P A SG11201702135P A SG 11201702135PA SG 11201702135P A SG11201702135P A SG 11201702135PA
Authority
SG
Singapore
Prior art keywords
metastases
solid cancers
treating solid
medicaments
predicting
Prior art date
Application number
SG11201702135PA
Inventor
Josef Straub
Eike Staub
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201702135PA publication Critical patent/SG11201702135PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201702135PA 2014-09-17 2015-08-18 A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof SG11201702135PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051530P 2014-09-17 2014-09-17
PCT/EP2015/001699 WO2016041614A1 (en) 2014-09-17 2015-08-18 A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof

Publications (1)

Publication Number Publication Date
SG11201702135PA true SG11201702135PA (en) 2017-04-27

Family

ID=53969334

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702135PA SG11201702135PA (en) 2014-09-17 2015-08-18 A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof

Country Status (14)

Country Link
US (2) US11415581B2 (en)
EP (1) EP3193927B1 (en)
JP (2) JP7372025B2 (en)
KR (1) KR20170052690A (en)
CN (1) CN107073111A (en)
AU (2) AU2015317409A1 (en)
BR (1) BR112017005336A2 (en)
CA (1) CA2961421C (en)
ES (1) ES2856348T3 (en)
IL (1) IL251078B (en)
MX (1) MX2017003015A (en)
RU (1) RU2017112998A (en)
SG (1) SG11201702135PA (en)
WO (1) WO2016041614A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106714835A (en) 2014-09-17 2017-05-24 默克专利股份公司 A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
CN108957014A (en) * 2018-09-27 2018-12-07 郑州大学第附属医院 Colorectal cancer blood serum designated object, expression appraisal procedure, kit and application
CN113015747A (en) * 2018-10-19 2021-06-22 默克专利股份公司 Abitumumab for the treatment of colorectal cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282603B6 (en) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanized and chimeric monoclonal antibody, expression vector and pharmaceutical preparation
ES2202336T3 (en) 1994-12-20 2004-04-01 Merck Patent Gmbh MONOCLONAL ANTIBODY AGAINST INTEGRIN ALFA-V.
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
SK13512003A3 (en) 2001-05-02 2004-08-03 Novartis Ag Pharmaceutical uses of bisphosphonates
AU2003211877A1 (en) 2002-03-11 2003-09-22 Takeda Chemical Industries, Ltd. Remedies for sex hormone-dependent disease
JP2004002321A (en) 2002-03-11 2004-01-08 Takeda Chem Ind Ltd Therapeutic agent for sex hormone dependent disease
EP1895302A3 (en) 2003-04-08 2008-05-14 Colotech A/S A method of detecting of colorectal cancer in human samples
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
WO2007103116A2 (en) * 2006-03-02 2007-09-13 Laboratory Corporation Of America Holdings Methods and systems for evaluating health risk factors by measurement of dna damage and dna repair
BRPI0815567B8 (en) 2007-07-17 2021-05-25 Merck Patent Gessellschaft Mit Beschraenkter Haftung engineered anti-alpha v-integrin hybrid antibodies, fusion protein and pharmaceutical composition
JP5403534B2 (en) * 2008-10-29 2014-01-29 インフォコム株式会社 Methods to provide information for predicting prognosis of esophageal cancer
MX2011006675A (en) * 2008-12-23 2011-07-12 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity.
KR20160021308A (en) * 2008-12-23 2016-02-24 제넨테크, 인크. Methods and compositions for diagnostic use in cancer patients
WO2010096627A1 (en) * 2009-02-20 2010-08-26 Lisanti Michael P Therapeutics and methods for treating neoplastic diseases comprising determining the level of caveolin-1 and/or caveolin-2 in a stromal cell sample
EA201200025A1 (en) * 2009-06-19 2012-07-30 Мерк Патент Гмбх BIOMARKERS AND METHODS FOR DETERMINING THE EFFICIENCY OF ANTI-EGFR ANTIBODIES FOR THE TREATMENT OF MALIGNANT NORMALIZATION
CA2772670A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
EP2606349A4 (en) 2010-08-20 2014-04-30 Univ Jefferson Cancer diagnostic and cancer therapeutic
EP3415162A1 (en) 2011-02-11 2018-12-19 Merck Patent GmbH Anti-alpha-v integrin antibody for the treatment of prostate cancer
SG194615A1 (en) * 2011-05-25 2013-12-30 Novartis Ag Biomarkers for lung cancer
US20140154264A1 (en) 2011-06-02 2014-06-05 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
CA2867588A1 (en) 2012-03-30 2013-10-03 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
CN106714835A (en) 2014-09-17 2017-05-24 默克专利股份公司 A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases

Also Published As

Publication number Publication date
RU2017112998A (en) 2018-10-17
MX2017003015A (en) 2017-05-23
EP3193927B1 (en) 2020-11-25
EP3193927A1 (en) 2017-07-26
WO2016041614A1 (en) 2016-03-24
JP7242617B2 (en) 2023-03-20
CN107073111A (en) 2017-08-18
AU2015317409A1 (en) 2017-04-27
ES2856348T3 (en) 2021-09-27
IL251078B (en) 2021-05-31
KR20170052690A (en) 2017-05-12
BR112017005336A2 (en) 2017-12-12
AU2021203352A1 (en) 2021-06-24
CA2961421C (en) 2024-01-30
US20220334117A1 (en) 2022-10-20
IL251078A0 (en) 2017-04-30
US11415581B2 (en) 2022-08-16
US20170298134A1 (en) 2017-10-19
CA2961421A1 (en) 2016-03-24
RU2017112998A3 (en) 2019-03-28
JP2021009154A (en) 2021-01-28
JP7372025B2 (en) 2023-10-31
JP2017535516A (en) 2017-11-30

Similar Documents

Publication Publication Date Title
HK1251614A1 (en) Method for the treatment of malignancies
HK1254358A1 (en) Agents, uses and methods for the treatment of synucleinopathy
IL284577A (en) Gene therapy
GB201508025D0 (en) Fabry disease gene therapy
PT3204207T (en) Method for the further processing of a prefabricated product, and associated prefabricated product
HK1257519A1 (en) Methods and materials for galgt2 gene therapy
SG11201702132WA (en) A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
GB201408673D0 (en) Medicaments,uses and methods
SG11201703631VA (en) Novel carbodiimides, method for the production and use thereof
PL3313927T3 (en) Dilithium initiators
IL265762A (en) Dosing regimen of avelumab for the treatment of cancer
ZA201608820B (en) Method for treating drug resistant cancer
SG11201702135PA (en) A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
PL3023210T3 (en) Method for the treatment of distributable goods
PL3151899T3 (en) Device for the treatment of esophageal stenoses
IL263085A (en) Gene therapy
GB201806609D0 (en) A method of treatment and prognosis
GB201617715D0 (en) Methods for the treatment and prevention of ebola
GB201616470D0 (en) Method of predicting the liklihood of success of gene therapy
GB201616821D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201617591D0 (en) Methods for the treatment and prevention of ebola
GB201617590D0 (en) Methods for the treatment and prevention of ebola
GB201518489D0 (en) Methods for the treatment and prevention of ebola